Professor Gary Ford Chair of the AHSN Network and Chief Executive of Oxford AHSN
The AHSN Network has an extensive history in working to tackle the major cardiovascular risk conditions that if untreated can lead to heart attacks, strokes and other adverse cardiovascular events.
Since 2015, all 15 AHSNs have supported work on the detection and anticoagulation of atrial fibrillation (AF) leading to the avoidance of over 11,000 strokes.
Subsequently we have coordinated work improving lipid lowering management and improving the detection of familial hypercholesterolemia (FH). People are now receiving more intensive cholesterol lowering therapy including innovative drugs in some cases, to reduce their risk of developing heart attacks or stroke.
However, the pandemic had an adverse impact on the detection and management of cardiovascular disease (CVD) risk factors including hypertension. In June 2022, nearly 2 million fewer people with hypertension were recorded as being treated to target compared with the previous year (Quality and Outcomes Framework 20/21). This is why NHS England commissioned the AHSN Network to deliver this new national Blood Pressure Optimisation (BPO) programme building on our CVD portfolio of work to tackle this pressing health need.
It demonstrates our collective impact in delivering on our ambition to transform as many lives as possible through the rapid uptake of high value innovations. I extend my congratulations and thanks to all my colleagues from across the Network for their unwavering commitment to ensuring more patients benefit faster from innovation and service improvements that we support the health system to adopt.
The NHS Innovation Accelerator (NIA) has revealed its 2025 cohort of Fellows. As the NIA celebrates a decade of helping to drive innovation in the NHS, this year’s cohort aligns with the Government’s three priorities: supporting the transition from analogue to digital, sickness to prevention and hospital to home. The 28 new Fellows will benefit [...]
A new guide aimed at helping primary care organisations and integrated care boards understand and address problematic polypharmacy has been launched by the Health Innovation Network as part of its national Polypharmacy Programme. Developed in response to a clear need identified by primary care and prescribing colleagues, this essential resource provides practical, evidence-based strategies to [...]
Across England, innovation is improving cancer services and patient outcomes. Last week the government launched an open call for evidence to inform the National Cancer Plan. Innovation has a critical role to play in supporting the delivery of any National Cancer Plan, and delivering on the government’s three shifts. In order to realise the significant [...]
